338414-90-7

Usage

InChI:InChI=1/C12H14N2OS/c1-16-12-13-7-11(9-15)14(12)8-10-5-3-2-4-6-10/h2-7,15H,8-9H2,1H3

Upstream product

• 98412-23-8 1-benzyl-2-mercapto-5-hydroxymethyl-imidazole 
• 3287-99-8 benzylamine hydrochloride 
• 98412-23-8 5-hydroxymethyl-1-phenylmethylimidazoline-2(3H)-thione 
• 74-88-4 methyl iodide 

Downstream Products

• 479400-30-1 1-benzyl-2-(methylsulfanyl)imidazole-5-carbaldehyde 
• 207302-32-7 1-benzyl-2-methylsulfanyl-1,4-dihydro-pyrrolo[2,3-d]imidazole-5-carboxylic acid ethyl ester 
• 479500-76-0 C₁₃H₁₄N₄O₂S 
• 479500-75-9 1-benzyl-2-methylsulfanylimidazole-5-carboxylic acid hydrazide 
• 403479-30-1 1-benzyl-2-(methylsulfanyl)imidazole-5-carboxylic acid 
• 479500-74-8 1-benzyl-2-methylsulfanylimidazole-5-carboxylic acid methyl ester 
• 479400-34-5 diethyl 1,4-dihydro-2,6,-dimethyl-4-(1-phenylmethyl-2-methylthio-5-imidazolyl)pyridine-3,5-dicarboxylate 
• 479400-33-4 dimethyl 1,4-dihydro-2,6,-dimethyl-4-(1-phenylmethyl-2-methylthio-5-imidazolyl)pyridine-3,5-dicarboxylate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors

Novel imidazole-chalcone derivatives were designed and synthesized as tubulin polymerization inhibitors and anticancer agents. The antiproliferative activity of the imidazole-chalcone was assessed on some human cancer cell lines including A549 (adenocarci

Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents

A newly designed series of imidazolyl-methyl- l-2,4-thiazolidinediones 9 (a-m) were synthesized and In Silico studies were carried out to rationalize their anti-diabetic activity. Generally, all newly synthesized thiazolidinediones had anti-hyperglycemic activity compared with a diabetic-control group, without toxicity in 3T3 cells (viability ≥ 90%). These studies revealed that the compounds 9e and 9b (11?10-6mol/kg) lowered blood glucose more effectively when compared to pioglitazone at the same dose. Following the administration of compound 9e, no weight gains or any serious side effects on liver and pancreas were observed. Moreover, the glucose consumption assay results showed a significant glucose-lowering effect (p 0.001) in HepG2 cells, which were exposed to 11 mM of glucose at concentrations of 1.25–10 mM of compound 9e. Also, the PPAR-γ gene expression study revealed that pioglitazone and 9e showed similar behavior relative to the control group.

Synthesis of 4-(1-phenylmethyl-5-imidazolyl)-1,4-dihydropyridines as calcium channel antagonists

o-Nitrophenyl group of nifedipine has been replaced with 2-alkylthio-1-phenylmethyl-5-imidazolyl substituent. Starting from dihydroxyacetone and phenylmethylamine hydrochloride, 2-alkythio-1-phenylmethyl-5-formylimidazole 3 is first synthesized and subsequently used in synthesizing symmetrical (5a-f) and asymmetrical (6a,b) dihydropyridines.

Syntheses of substituted 2-(2-alkylthio-1-benzyl-5-imidazolyl)-1,3,4-oxadiazoles

Starting from the readily available benzylamine hydrochloride a series of 2-(2-alkylthio-1-benzyl-5imidazolyl)-1,3,4-oxadiazoles were prepared.

Synthesis and anti-inflammatory activity of 1-benzyl-2-(X-thio)pyrrolo[2,3-d]imidazole-5-carboxylates

A series of 1-benzyl-2-(X-thio)pyrrolo[2,3-d]imidazo were synthesized and tested as anti-inflammatory agents. Indomethacin and aspirin were used as reference drugs. All compounds except 6d had almost the same activity against carrageenan-induced oedema in